VICCBRE1002-A Phase II Study of the PARP Inhibitor, BSI-201, in Combination with Chemotherapy to Treat Triple Negative Breast Cancer in Brain Metastasis.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iniparib (Primary) ; Carboplatin; Gemcitabine
Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Sponsors Sanofi

02 Jun 2017 Results (n=1368) assessing the association of a four-gene decision tree signature with response to platinum-based chemotherapy in patients with triple negative breast cancer including patients from EFC11486 and PrECOG0105 trials, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
13 Jan 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
12 Dec 2015 Results of pooled analysis from this and other four trials presented at the 38th Annual San Antonio Breast Cancer Symposium.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com